| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
EGFR (C797S/T790M/L858R) 0.0002 μM (IC50)
EGFR (wild-type and mutant forms). EGFR-IN-17 is a potent and selective inhibitor of EGFR, specifically designed to overcome the C797S mutation which causes resistance to third-generation inhibitors like Osimertinib. |
|---|---|
| ln Vitro |
EGFR-IN-17 is a potent and selective EGFR inhibitor with an IC50 of 0.0002 uM (0.2 nM). It is designed to overcome C797S-mediated drug resistance. Its high potency allows for low-dose administration and makes it a critical tool for studying the mechanisms of resistance to third-generation EGFR inhibitors.
|
| ln Vivo |
EGFR-IN-17 is a potent inhibitor of EGFR designed to overcome C797S-mediated resistance. Its target selectivity suggests it is effective in vivo against tumors harboring this resistance mutation. It is used for cancer research to evaluate new therapeutic strategies for NSCLC patients who have progressed on Osimertinib or other third-generation inhibitors.
|
| Enzyme Assay |
Cell-free EGFR kinase assays are performed using recombinant human EGFR enzymes, including the wild-type and C797S mutant. The compound is incubated with the enzyme and a peptide substrate in the presence of ATP for 30-60 minutes. Kinase activity is measured using an ADP-Glo luminescence detection kit. The IC50 (0.0002 microM) is calculated from a dose-response curve.
|
| Cell Assay |
NSCLC cell lines engineered to express the C797S resistance mutation are seeded in 96-well plates and treated with increasing concentrations of EGFR-IN-17 for 72 hours. Cell viability is measured using the CellTiter-Glo reagent. The inhibition of EGFR phosphorylation (p-EGFR) and downstream signaling (p-AKT, p-ERK) is measured by Western blot.
|
| Animal Protocol |
For in vivo studies, EGFR-IN-17 would be administered orally to mice bearing xenografts of C797S-mutant NSCLC cells. Dosing regimens are not specified. Tumor volumes would be measured with calipers. At study termination, tumors would be excised for pharmacodynamic analysis of EGFR phosphorylation and for immunohistochemistry to assess proliferation markers.
|
| ADME/Pharmacokinetics |
No specific pharmacokinetic data are reported for EGFR-IN-17. The molecular weight is 568.01 (C27H31ClN7O3P). It is soluble in DMSO (12.5 mg/mL). For in vivo studies, it would be formulated in a vehicle such as 0.5% methylcellulose. Its half-life, oral bioavailability, and clearance have not been characterized. It is stored at -20degC.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are reported for EGFR-IN-17. As a highly potent and selective EGFR inhibitor, its safety profile is expected to be manageable. The compound is for research use only and is not approved for human use. Comprehensive toxicological assessments have not been published.
|
| References | |
| Additional Infomation |
Other information: EGFR-IN-17 (CAS 2817679-31-3) is a research compound, not FDA-approved. It is a potent and selective EGFR inhibitor with an IC50 of 0.0002 microM. It is specifically designed to overcome C797S-mediated resistance to third-generation EGFR inhibitors. It is a valuable tool for studying drug resistance in NSCLC. For research use only.
|
| Exact Mass |
567.191
|
|---|---|
| CAS # |
2817679-31-3
|
| PubChem CID |
162640600
|
| Appearance |
Off-white to light yellow solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
39
|
| Complexity |
833
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN1C=C(C=N1)C2=CC(=C(C=C2N3CCOCC3)OC)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl
|
| InChi Key |
LLUHSVVGRQBIMO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H31ClN7O3P/c1-34-17-18(15-30-34)19-13-22(24(37-2)14-23(19)35-9-11-38-12-10-35)32-27-29-16-20(28)26(33-27)31-21-7-5-6-8-25(21)39(3,4)36/h5-8,13-17H,9-12H2,1-4H3,(H2,29,31,32,33)
|
| Chemical Name |
5-chloro-4-N-(2-dimethylphosphorylphenyl)-2-N-[2-methoxy-5-(1-methylpyrazol-4-yl)-4-morpholin-4-ylphenyl]pyrimidine-2,4-diamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 12.5 mg/mL (22.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.20 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (2.20 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (2.20 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
